Human GM130/GOLGA2 Antibody

Detection of Human GM130/GOLGA2 by Western Blot. Western blot shows lysates of MCF-7 human breast cancer cell line and ZR-75 human breast cancer cell line. PVDF membrane was probed with 0.25 µg/mL of Sheep Anti-Human GM130/GOLGA2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF8199) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for GM130/GOLGA2 at approximately 130 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.

GM130/GOLGA2 in HeLa Human Cell Line. GM130/GOLGA2 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line using Sheep Anti-Human GM130/GOLGA2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF8199) at 1.7 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Sheep IgG Secondary Antibody (red; Catalog # NL010) and counterstained with DAPI (blue). Specific staining was localized to Golgi apparatus vesicles. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

Detection of Human GM130/GOLGA2 by Simple Western^TM. Simple Western lane view shows lysates of HeLa human cervical epithelial carcinoma cell line, MCF-7 human breast cancer cell line, and ZR-75 human breast cancer cell line, loaded at 0.2 mg/mL. A specific band was detected for GM130/GOLGA2 at approximately 141 kDa (as indicated) using 50 µg/mL of Sheep Anti-Human GM130/GOLGA2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF8199) followed by 1:50 dilution of HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Detection of Mouse GM130/GOLGA2 by Immunocytochemistry/Immunofluorescence Kcnj13 orchestrates SM cell alignment and polarity. a Immunostaining for alpha SMA (red) and DAPI staining (blue) in dorsal views of E14.5 WT (n = 8) and Kcnj13T38C/T38C (n = 8) tracheas. b Quantification of E14.5 WT (n = 8) and Kcnj13T38C/T38C (n = 8) tracheal SM cell orientation. c Quantification of E14.5 WT (n = 8) and Kcnj13T38C/T38C (n = 8) tracheal SM cell nuclear aspect ratio (NAR). d Immunostaining for alpha SMA (red) and DAPI staining (blue) of transverse sections of E14.5 WT (n = 10) and Kcnj13T38C/T38C (n = 10) tracheas. e Quantification of WT (n = 10) and Kcnj13T38C/T38C (n = 10) tracheal SM cell layers. f Immunostaining for alpha SMA (red) and GM130 (green) and DAPI staining (blue) in dorsal views of E14.5 WT (n = 8) and Kcnj13T38C/T38C (n = 8) tracheas. g Quantification of WT (n = 8) and Kcnj13T38C/T38C (n = 8) Golgi apparatus (green) position relative to the nucleus (blue). h Timeline for tamoxifen administration. i Immunostaining for KCNJ13 (red), alpha SMA (green), and DAPI staining (blue) of transverse sections of E14.5 control (n = 6) and Myh11-CreERT2;Kcnj13flox/flox (n = 6) tracheas. j Representative images of ventral views of E14.5 control (n = 9) and Myh11-CreERT2;Kcnj13flox/flox (n = 9) tracheas. Double-sided arrows indicate tracheal tube length. k Quantification of E14.5 control (n = 9) and Myh11-CreERT2;Kcnj13flox/flox (n = 9) tracheal tube length. l Immunostaining for alpha SMA (red) and DAPI staining (blue) in dorsal views of E14.5 control (n = 9) and Myh11-CreERT2;Kcnj13flox/flox (n = 9) tracheas. m Quantification of E14.5 control (n = 9) and Myh11-CreERT2;Kcnj13flox/flox (n = 9) tracheal SM cell orientation. n Immunostaining for SOX9 (green) in ventral views of E15.5 control (n = 6) and Myh11-CreERT2;Kcnj13flox/flox (n = 6) tracheas. Arrows point to tracheal mesenchymal condensations. Scale bars: 1000 μm (j), 100 μm (n), 50 μm (d), 20 μm (a, f, i, l). *P < 0.05; **P < 0.01; unpaired Student’s t-test, mean ± s.d Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/30022023), licensed under a CC-BY license. Not internally tested by R&D Systems.